


# Neoadjuvant chemotherapy use up in ovarian cancer treatment

12 September 2016



"Future studies should prospectively consider the efficacy of NACT by extent of residual disease in unselected patients," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

**More information:** [Abstract](#)  
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

(HealthDay)—For patients with stage IIIC to IV ovarian cancer, neoadjuvant chemotherapy (NACT) use increased from 2003 to 2012, according to a study published online Sept. 6 in the *Journal of Clinical Oncology*.

Larissa A. Meyer, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues examined the use of NACT versus primary cytoreductive surgery (PCS) in a multi-center observational study. Data were included for 1,538 women with stages IIIC to IV [ovarian cancer](#) who were diagnosed between 2003 and 2012. Overall survival, morbidity, and postoperative residual disease were compared in a propensity-score matched sample of 594 patients.

The researchers found that from 2003-2010 to 2011-2012 there was an increase in NACT use from 16 to 34 percent in stage IIIC disease and from 41 to 62 percent in stage IV disease (both

$P_{\text{trend}}$

APA citation: Neoadjuvant chemotherapy use up in ovarian cancer treatment (2016, September 12) retrieved 10 June 2022 from <https://medicalxpress.com/news/2016-09-neoadjuvant-chemotherapy-ovarian-cancer-treatment.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*